Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of N-Nitroso Desmethyl Chlorpromazine above the recommended intake limit
| Brand name | CHLORPROMAZINE HYDROCHLORIDE |
| Generic name | CHLORPROMAZINE HYDROCHLORIDE |
| Active ingredient(s) | CHLORPROMAZINE HYDROCHLORIDE |
| Distributed by / for | Major Pharmaceuticals, Indianapolis, IN 46268, USA |
| NDC | 0904-7130-61 |
| Full product label | Major ChlorproMAZINE Hydrochloride Tablets, USP, 25 mg, 100 Tablets (10x10) blister package, Rx Only, Packaged and Distributed by Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-7130-61, UPC (01)00309047130610 |
| Recalling firm | The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories |
| Distribution | Nationwide |
| Quantity | 1256 blister packs |
| Recall initiated | 2025-09-12 |
| Report date | 2025-10-15 |
| Recall completed | — |
| Recall number | D-0010-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | La Vergne TN United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗